We are monitoring the impact of COVID-19 on Europe Antiviral Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1510
Share on
Share on

Europe Antiviral Drugs Market Research Report - Segmented By Application ,Target, End Users & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe)- Industry Analysis, Size, Share, Growth, Trends, & Forecasts | 2021 to 2026

Pulished: April, 2021
ID: 1510
Pages: 136

Europe Antiviral Drugs Market Size & Growth (2021 to 2026):

As per the research report, the size of the Europe Antiviral Drugs Market is valued at USD 9.47 billion in 2021 and is expected to reach USD 12.07 billion by 2026, growing at a CAGR of 4.98% during the forecast period 2021 to 2026.

DRIVERS

The increasing prevalence of HIV disease around the world will drive the demand for antiviral drugs in the coming period.

When used according to directions, antiviral drugs can often help reduce the duration of flu symptoms in healthier children and adults and can reduce the severity of common flu symptoms. Therefore, these factors help promote the usage of antiviral drugs for the treatment of viral infections around the world. Hence, the increasing prevalence of viral infections, such as HIV and influenza, along with increasing R&D activities and development of newer and advanced formulations, are the few factors responsible for the high growth rate of the market during the forecast period.

The generic antiviral drugs segment is growing steadily in the European antiviral drug market. By 2027, the segment is expected to claim a significant market share in terms of revenue, owing to the increased consumption of generic antiviral drugs in recent times. The use of generic drugs can drastically reduce the overall hospital expense of the patient. Unlike expensive brand name drugs, many pharmaceutical companies in the region have introduced cost-effective alternatives to meet the need for effective drugs amid the pandemic.

RESTRAINTS

The high cost of drug development coupled with the availability of alternative treatment options such as homeopathy and naturopathy are the few major factors inhibiting the growth of the market during the forecast period 2020-2027.

OPPORTUNITIES

The alarming rate of the spread of the coronavirus has also led to a marked increase in the use of antiviral drugs to treat viral infections in European countries. The use of antiviral drugs can greatly reduce the effect of the SARS-CoV-2 virus to some extent.

When used with other medications and necessary precautionary measures, such as self-isolation, quarantine, and contact tracing, they have been shown to be an effective management solution for COVID-19 patients with mild to moderate symptoms. The trend authorization of prescription drugs has accelerated the forecast for the antiviral drug market in Europe.

CHALLENGES

Factors such as government policy approval and competition between different brands can prove to be challenges in this market.

This research report on the Europe antiviral drugs market has been segmented and sub-segmented into the following categories:

By Application: 

  • HIV/AIDS
  • Hepatitis
  • Herpes
  • Influenza
  • Others

By Target: 

  • DNA Polymerase
  • NS3 Protease
  • Reverse Transcriptase
  • Others

By End Users: 

  • Hospitals
  • Research Institutes
  • Laboratory Centers

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

REGIONAL ANALYSIS

According to WHO and UNAIDS estimates, 37.7 million people were living with HIV worldwide at the end of 2017. In 2018, around 2.9 million people were infected for the first time and 1.3 million people have died from HIV-related causes. The UK leads the European market, with having more HIV infections and hence growth in antiviral drugs group. Pharmaceutical companies are focusing on R&D to introduce new drugs with greater medical and commercial potential. These companies invest mainly in R&D activities with the aim of offering innovative and high quality products to the market. According to the British Pharmaceutical Industry Association, pharmaceutical R&D spending in the UK increased by more than 15% in 2018, reaching an estimated US $ 5.55 billion. The UK has relative stability compared to the rest of European countries as an investment base for increasing R&D activities of the three largest pharmaceutical investors.

Key players operating in the Europe Antiviral Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA), and Abbott Laboratories (USA).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 HIV/AIDS

                                5.1.3 Hepatitis  

                                5.1.4 Herpes     

                                5.1.5 Influenza 

                                5.1.6 Others      

                                5.1.7 Y-o-Y Growth Analysis, By Application         

                                5.1.8 Market Attractiveness Analysis, By Application        

                                5.1.9 Market Share Analysis, By Application         

                5.2 Target                           

                                5.2.1 Introduction           

                                5.2.2 DNA polymerase  

                                5.2.3 NS3 Protease         

                                5.2.4 Reverse transcriptase        

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By Target   

                                5.2.7 Market Attractiveness Analysis, By Target

                                5.2.8 Market Share Analysis, By Target   

                5.3 End Users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals/Clinics   

                                5.3.3 Research Institutes             

                                5.3.4 Laboratory Centers             

                                5.3.5 Y-o-Y Growth Analysis, By End Users            

                                5.3.6 Market Attractiveness Analysis, By End Users          

                                5.3.7 Market Share Analysis, By End Users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Target

                                                6.1.3.4 By End-Users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Target

                                                6.1.4.4 By End-Users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Target

                                                6.1.5.4 By End-Users

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Johnson & Johnson                 

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis International AG                     

                8.3 Roche Holding AG                   

                8.4 Pfizer                            

                8.5 Merck and Co. Inc                    

                8.6 GlaxoSmithKline plc                

                8.7 AstraZeneca AB                        

                8.8 Gilead Sciences                         

                8.9 Abbott Laboratories               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Antiviral Drugs Market By Application, From 2021 to 2026 ( USD Billion )
  2. Europe HIV/AIDS  Market By Region, From 2021 to 2026 ( USD Billion )
  3. Europe Hepatitis Market By Region, From 2021 to 2026 ( USD Billion )
  4. Europe Herpes Market By Region, From 2021 to 2026 ( USD Billion )
  5. Europe Influenza Market By Region, From 2021 to 2026 ( USD Billion )
  6. Europe Others Market By Region, From 2021 to 2026 ( USD Billion )
  7. Europe Antiviral Drugs Market By Target, From 2021 to 2026 ( USD Billion )
  8. Europe DNA polymerase Market By Region, From 2021 to 2026 ( USD Billion )
  9. Europe NS3 Protease Market By Region, From 2021 to 2026 ( USD Billion )
  10. Europe Reverse transcriptase Market By Region, From 2021 to 2026 ( USD Billion )
  11. Europe Others Market By Region, From 2021 to 2026 ( USD Billion )
  12. Europe Antiviral Drugs Market By End User, From 2021 to 2026 ( USD Billion )
  13. Europe Hospitals/Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  14. Europe Research Institutes Market By Region, From 2021 to 2026 ( USD Billion )
  15. Europe Laboratory Centers Market By Region, From 2021 to 2026 ( USD Billion )
  16. U.K. Antiviral Drugs Market By Application, From 2021 to 2026 ( USD Billion )
  17. U.K. Antiviral Drugs Market By Target, From 2021 to 2026 ( USD Billion )
  18. U.K. Antiviral Drugs Market By End User, From 2021 to 2026 ( USD Billion )
  19. Germany Antiviral Drugs Market By Application, From 2021 to 2026 ( USD Billion )
  20. Germany Antiviral Drugs Market By Target, From 2021 to 2026 ( USD Billion )
  21. Germany Antiviral Drugs Market By End User, From 2021 to 2026 ( USD Billion )
  22. France Antiviral Drugs Market By Application, From 2021 to 2026 ( USD Billion )
  23. France Antiviral Drugs Market By Target, From 2021 to 2026 ( USD Billion )
  24. France Antiviral Drugs Market By End User, From 2021 to 2026 ( USD Billion )
  25. Italy Antiviral Drugs Market By Application, From 2021 to 2026 ( USD Billion )
  26. Italy Antiviral Drugs Market By Target, From 2021 to 2026 ( USD Billion )
  27. Italy Antiviral Drugs Market By End User, From 2021 to 2026 ( USD Billion )
  28. Spain Antiviral Drugs Market By Application, From 2021 to 2026 ( USD Billion )
  29. Spain Antiviral Drugs Market By Target, From 2021 to 2026 ( USD Billion )
  30. Spain Antiviral Drugs Market By End User, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample